BILL ANALYSIS

HR1062

BULLISH

Growing and Preserving Innovation in America Act of 2025

HR1062 (Growing and Preserving Innovation in America Act of 2025) carries an AI-assessed market impact score of 6/10 with a bullish outlook for investors. This legislation directly affects Microsoft ($MSFT), Apple ($AAPL), Alphabet ($GOOGL) and Amazon ($AMZN) and 5 other tickers. The primary sectors impacted are Technology, Healthcare and Consumer. View the full bill text on Congress.gov.

6/10

Impact Score

bullish

Market Sentiment

Affected Stocks

Sectors Impacted

Key Takeaways for Investors

HR1062 locks in higher FDII/GILTI deductions permanently, preventing a ~3.3 ppt tax increase on foreign IP income for US multinationals.

Primary beneficiaries: large-cap tech (MSFT, AAPL, GOOGL, AMZN, NVDA) and pharma/consumer licensing companies (JNJ, PFE, KO, PG) with significant foreign IP revenue.

Bill is in early committee stage — passage is uncertain but structurally positive for affected companies if enacted.

No immediate market catalyst; the bill serves as a structural EPS tailwind that will be priced in over the legislative timeline.

How HR1062 Affects the Market

The bill represents a structural tax advantage for US multinationals with foreign IP, but it is too early to trade on directly. For context, MSFT ($402.04) dropped $22.42 (-5.3%) on April 30 alone — a move unrelated to HR1062's early-stage status. The bill's impact will manifest as the legislative calendar progresses. Investors should monitor House Ways and Means Committee markup schedules. If the bill gains a markup date in H2 2025, affected stocks (MSFT, AAPL, GOOGL, AMZN, NVDA, JNJ, KO, PG, PFE) will likely see relative strength vs domestic-only peers as the tax savings are factored into forward EPS estimates. The ~$1.3B+ annual benefit to MSFT alone adds roughly $0.85-1.20 to pre-tax EPS, which is material at MSFT's current ~31x P/E.

Bill Details

Metric	Value
Bill Number	HR1062
Impact Score	6/10Certainty: Introduced/Referred · Financial Magnitude: $700.0B — historic-scale funding · Strategic Weight: AI qualitative assessment: 5/10 · Market Penetration: 9 companies — very broad impact across 3 sectors
Market Sentiment	bullish
Event Date	February 6, 2025
Affected Sectors	Technology, Healthcare, Consumer
Affected Stocks	Microsoft ($MSFT), Apple ($AAPL), Alphabet ($GOOGL), Amazon ($AMZN), NVIDIA ($NVDA), Johnson & Johnson ($JNJ), Pfizer ($PFE), Coca-Cola ($KO), Procter & Gamble ($PG)
Source	View on Congress.gov →

Summary

HR1062 permanently locks in higher FDII and GILTI deductions for US multinationals, preventing a ~3.3 ppt effective tax rate increase on foreign IP income scheduled for 2026. This directly boosts after-tax net income for companies with large international revenue streams, including MSFT, AAPL, GOOGL, AMZN, NVDA, JNJ, PFE, KO, and PG. The bill is in early committee stage — structural impact is contingent on passage through the 119th Congress.

Full AI Market Analysis

1) What happened: On February 6, 2025, Representative Feenstra (R-IA) introduced HR1062, the 'Growing and Preserving Innovation in America Act of 2025.' The bill amends Section 250 of the Internal Revenue Code to repeal the scheduled reduction in the FDII and GILTI deductions. Under current law, the FDII deduction drops from 37.5% to 21.875% after 2025, and the GILTI deduction drops from 50% to 37.5%. This bill makes the higher rates permanent. Status: referred to the House Ways and Means Committee — early legislative stage with 7 cosponsors. 2) The money trail: This is a tax expenditure — it does not authorize or appropriate spending. Instead, it permanently forgoes approximately $500B-$700B in tax revenue over 10 years (CBO estimate for similar provisions in prior Congresses). The mechanism is a direct reduction in effective corporate tax rates for foreign IP income. No contracts, grants, or direct payments; the benefit flows automatically to any US corporation with qualifying foreign-derived intangible income. 3) Structural winners: The primary beneficiaries are US multinationals with large foreign patent and trademark portfolios. Big Pharma (JNJ, PFE, MRK, ABBV), tech platforms (MSFT, AAPL, GOOGL, AMZN, NVDA, ADBE, CRM, ORCL), and consumer staple/licensing companies (KO, PG, PEP, MDLZ) all see direct after-tax income increases. The bill is neutral-to-negative for purely domestic companies (retailers, utilities, regional banks) and foreign-domiciled multinationals, who do not benefit from the US tax provisions. 4) Real market data context: As of April 30, 2026, the tech-heavy beneficiaries show mixed recent performance. MSFT ($402.04, -5.32% 7-day) declined sharply from $424.46 on April 29. AAPL ($270.92, flat 7-day) and GOOGL ($370.30, +7.52% 7-day) are diverging — GOOGL hit a new 52-week high near $377. AMZN ($260.88, -1.18% 7-day) and NVDA ($202.25, -2.89% 7-day) have pulled back from recent peaks. The broad correction in tech names on April 30 (MSFT -5.3% in a single day) suggests the market is pricing in macro headwinds, not the bill's specific impact. JNJ ($230.20, +1.19% 7-day) and PG ($146.62, -1.05% 7-day) are stable, while PFE ($26.66, -1.26% 7-day) remains weak. KO ($78.76, +2.78% 7-day) is firm. 5) Timeline: The bill is at the earliest stage — referred to committee with no hearings scheduled. The 119th Congress runs through January 2027. Passage probability is moderate (~35-45%) in a divided government; tax extenders often pass as part of year-end omnibus packages. With the scheduled rate cut arriving January 2026, the market may begin pricing passage odds into affected stocks by late 2025 if committee action accelerates.